Abstract | BACKGROUND/AIMS: To determine the medium-term effect of travoprost on the daytime intraocular pressure (IOP) of patients with normal tension glaucoma (NTG) METHODS: Newly diagnosed NTG patients underwent baseline, daytime, hourly IOP phasing. Patients were randomised to either treatment or no treatment (control). Treatment comprised once daily topical travoprost 0.004%. After 6 months, the participants underwent their second IOP phasing. RESULTS: Data from 88 participants were analysed-54 were randomised to treatment and 34 to the control group. The mean duration of treatment was 6 months. The average, maximum and minimum diurnal IOPs for treated patients were statistically significantly lower than for control patients at follow-up (p<0.001). When compared with baseline IOP, the travoprost treated group demonstrated a decrease of 16.1%, 13.5% and 16.7% in the average IOP, maximum IOP, and minimum IOP respectively. Of those treated, about one-third achieved a decrease in average IOP of at least 20%; only about one-tenth achieved a reduction of at least 30%. CONCLUSION:
Travoprost monotherapy had a sustained hypotensive effect in NTG and achieved a reasonable or good response (>20% reduction in average IOP) in 32.9% of treated eyes. However, in the majority of eyes with NTG, travoprost monotherapy appeared unable to produce the desirable 30% reduction in average IOP.
|
Authors | G S Ang, J P Kersey, L Shepstone, D C Broadway |
Journal | The British journal of ophthalmology
(Br J Ophthalmol)
Vol. 92
Issue 8
Pg. 1129-33
(Aug 2008)
ISSN: 1468-2079 [Electronic] England |
PMID | 18511540
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antihypertensive Agents
- Cloprostenol
- Travoprost
|
Topics |
- Aged
- Antihypertensive Agents
(therapeutic use)
- Circadian Rhythm
- Cloprostenol
(analogs & derivatives, therapeutic use)
- Female
- Follow-Up Studies
- Glaucoma
(drug therapy, physiopathology)
- Humans
- Intraocular Pressure
(drug effects)
- Male
- Middle Aged
- Single-Blind Method
- Travoprost
- Treatment Outcome
|